The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
An article from
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
Published July 22, 2026
A GSK building in London
Courtesy of GSK
In a landmark moment for its oncology ambitions, GSK has
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
The acquisition is thought to be GSK’s biggest deal in more than a decade.
British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company…
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
